MedTrace Logo

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

NCT04623944 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2024-12-27

No results posted yet for this study

Summary

This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.

Conditions

  • Relapsed/Refractory AML
  • AML, Adult
  • MDS
  • Refractory Myelodysplastic Syndromes

Interventions

BIOLOGICAL

NKX101 - CAR NK cell therapy

NKX101 is an investigational allogeneic CAR NK product targeting NKG2D ligands on cancer cells. Part 2 will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX101 as determined in Part 1.

Sponsors & Collaborators

  • Nkarta, Inc.

    lead INDUSTRY

Principal Investigators

  • David Shook, MD · Nkarta, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2024-10-02
Completion
2039-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04623944 on ClinicalTrials.gov